Two patients with acute myeloid leukemia (AML) achieve remission. Both test positive for measurable residual disease (MRD). Both show the same mutation at a similar variant allele frequency. By ...
Divya Gupta, MD, assistant professor at Feinberg School of Medicine at Northwestern University, discussed the potential of using circulating tumor DNA and minimal residual disease (MRD) assays for ...
Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer in the United States Of 266 included patients, estimated relapse-free survival (RFS) and overall survival ...
Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment ...
Molecular residual disease (MRD) has grown in importance as an oncological biomarker 1. The use of tumor-informed liquid biopsy has proven effective in early detection of circulating tumor-derived DNA ...
MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation. It's been more than 20 years since ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT ...
Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1-2N0M0) Oral Tongue Squamous Cell Carcinoma Adults with FLT3-ITD AML in first remission underwent HCT and were randomly ...
Over the last decade, molecular residual disease (or minimal residual disease; MRD) has emerged as a powerful dynamic biomarker in oncology. Defined as a very small number of tumor cells remaining ...
The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results